BR112023024822A2 - Bcma como alvo para anticorpos de redirecionamento de células t em linfomas de células b - Google Patents

Bcma como alvo para anticorpos de redirecionamento de células t em linfomas de células b

Info

Publication number
BR112023024822A2
BR112023024822A2 BR112023024822A BR112023024822A BR112023024822A2 BR 112023024822 A2 BR112023024822 A2 BR 112023024822A2 BR 112023024822 A BR112023024822 A BR 112023024822A BR 112023024822 A BR112023024822 A BR 112023024822A BR 112023024822 A2 BR112023024822 A2 BR 112023024822A2
Authority
BR
Brazil
Prior art keywords
bcma
cell
target
lymphomas
redirecting antibodies
Prior art date
Application number
BR112023024822A
Other languages
English (en)
Portuguese (pt)
Inventor
P Kater Arnon
Frederik Eldering Eric
Adams Homer Iii
Raluca Verona
Original Assignee
Acad Medisch Ct
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acad Medisch Ct, Janssen Biotech Inc filed Critical Acad Medisch Ct
Publication of BR112023024822A2 publication Critical patent/BR112023024822A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
BR112023024822A 2021-05-28 2022-05-26 Bcma como alvo para anticorpos de redirecionamento de células t em linfomas de células b BR112023024822A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163194470P 2021-05-28 2021-05-28
US202163209694P 2021-06-11 2021-06-11
PCT/EP2022/064362 WO2022248642A1 (en) 2021-05-28 2022-05-26 Bcma as a target for t cell redirecting antibodies in b cell lymphomas

Publications (1)

Publication Number Publication Date
BR112023024822A2 true BR112023024822A2 (pt) 2024-02-20

Family

ID=82115891

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023024822A BR112023024822A2 (pt) 2021-05-28 2022-05-26 Bcma como alvo para anticorpos de redirecionamento de células t em linfomas de células b

Country Status (10)

Country Link
US (1) US20220411525A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347039A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024519545A (cg-RX-API-DMAC7.html)
KR (1) KR20240014482A (cg-RX-API-DMAC7.html)
CN (1) CN119679935A (cg-RX-API-DMAC7.html)
AU (1) AU2022281104A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024822A2 (cg-RX-API-DMAC7.html)
CA (1) CA3221399A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023014139A (cg-RX-API-DMAC7.html)
WO (1) WO2022248642A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116249548A (zh) 2020-05-11 2023-06-09 詹森生物科技公司 用于治疗多发性骨髓瘤的方法
EP4426437A4 (en) 2021-11-03 2025-09-17 Janssen Biotech Inc METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI811023B (zh) 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途
EP3615068A1 (en) * 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2019220368A1 (en) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
WO2021092060A1 (en) * 2019-11-05 2021-05-14 Engmab Sarl Methods of treatment

Also Published As

Publication number Publication date
WO2022248642A1 (en) 2022-12-01
US20220411525A1 (en) 2022-12-29
CA3221399A1 (en) 2022-12-01
CN119679935A (zh) 2025-03-25
EP4347039A1 (en) 2024-04-10
KR20240014482A (ko) 2024-02-01
MX2023014139A (es) 2023-12-13
JP2024519545A (ja) 2024-05-15
AU2022281104A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
BR112020015915A8 (pt) Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
EA202190630A1 (ru) Способы комбинированной терапии
BR112016029492A2 (pt) método para tratamento de linfoma não hodgkin
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
MX2021006347A (es) Metodos de tratamiento de cánceres que sobreexpresan whsc1 mediante la inhibición de setd2.
BR112018073920A2 (pt) inibidores de pd-1/pd-l1 para tratamento de câncer".
CY1123240T1 (el) Αντισωμα αντι fgf23 και μια φαρμακευτικη συνθεση που το περιλαμβανει
BRPI0617159B8 (pt) compostos de piridopirimidinone inibidores de pi3ka, composições que os contem e processo para preparo
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
BRPI0617165B1 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
BR112023014898A2 (pt) Quinolinas e azaquinolinas como inibidores de cd38
ECSP088762A (es) Tratamiento del dolor
MX2024002391A (es) Inhibidores de indolina de kif18a.
EA201590709A1 (ru) Комбинированная терапия и ее применение для лечения димиелинизирующих расстройств
BR112015024621A8 (pt) usos de dose unitária de unidades formadoras de colônia de c. novyi, composição farmacêutica compreendendo a referida dose unitária, kit para tratar ou atenuar um efeito de um tumor sólido presente em um ser humano e dose unitária de unidades formadoras de colônia de c. novyi
MX2020011817A (es) Metodos para tratar el linfoma.
PH12021550965A1 (en) Combination therapy for treatment of hematological diseases
MX2021004819A (es) Composiciones y metodos para tratar lesiones cerebrales.
BR112022025105A2 (pt) Método para o tratamento de câncer cervical em um indivíduo, conjugado anticorpo-fármaco, e, uso de um conjugado anticorpo-fármaco
WO2022047128A3 (en) Method for treating complement mediated disorders caused by betacoronaviruses
BR112017018758A2 (pt) alteração do metabolismo de esteroide para tratamento de doença dependente de esteroide
WO2019136157A3 (en) Reducing beta-catenin and ido expression to potentiate immunotherapy
MX2023014139A (es) Bcma como un objetivo para anticuerpos de redireccionamiento de celulas t en linfomas de celulas b.
BR112022018948A2 (pt) Métodos de tratamento de lesão pulmonar com inibidores de cgrp
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: JANSSEN BIOTECH, INC. (US) ; STICHTING AMSTERDAM UMC (NL)

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]